Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2023 22
2024 95
2025 65
2026 29

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

180 results

Results by year

Filters applied: . Clear all
Page 1
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Castro Narro GE, Chowdhury A, Cortez-Pinto H, Cryer DR, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot BG, Korenjak M, Kowdley KV, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell EE, Roden M, Romero-Gómez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN; NAFLD Nomenclature consensus group. Rinella ME, et al. J Hepatol. 2023 Dec;79(6):1542-1556. doi: 10.1016/j.jhep.2023.06.003. Epub 2023 Jun 24. J Hepatol. 2023. PMID: 37364790 Free article. Review.
This study set out to determine if content experts and patient advocates were in favour of a change in nomenclature and/or definition. A modified Delphi process was led by three large pan-national liver associations. ...An independent committee of experts external to the …
This study set out to determine if content experts and patient advocates were in favour of a change in nomenclature and/or definition …
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association.
Cusi K, Abdelmalek MF, Apovian CM, Balapattabi K, Bannuru RR, Barb D, Bardsley JK, Beverly EA, Corbin KD, ElSayed NA, Isaacs S, Kanwal F, Pekas EJ, Richardson CR, Roden M, Sanyal AJ, Shubrook JH, Younossi ZM, Bajaj M. Cusi K, et al. Diabetes Care. 2025 Jul 1;48(7):1057-1082. doi: 10.2337/dci24-0094. Diabetes Care. 2025. PMID: 40434108 Review.
However, most individuals and their health care professionals remain unaware of the severe hepatic or extrahepatic health risks associated with MASLD and the need for early identification. In recognition of this knowledge gap and the rising prevalence of MASLD, this …
However, most individuals and their health care professionals remain unaware of the severe hepatic or extrahepatic health risks associated w …
Steatotic liver disease, MASLD and risk of chronic kidney disease.
Bilson J, Mantovani A, Byrne CD, Targher G. Bilson J, et al. Diabetes Metab. 2024 Jan;50(1):101506. doi: 10.1016/j.diabet.2023.101506. Epub 2023 Dec 21. Diabetes Metab. 2024. PMID: 38141808 Free article. Review.
The name chosen to replace NAFLD was metabolic dysfunction-associated steatotic liver disease (MASLD). The change of nomenclature from NAFLD to MAFLD and then MASLD has resulted in a reappraisal of the epidemiological trends and associations with the risk of …
The name chosen to replace NAFLD was metabolic dysfunction-associated steatotic liver disease (MASLD). The change of nomenclature …
The pathophysiology of MASLD: an immunometabolic perspective.
Schwärzler J, Grabherr F, Grander C, Adolph TE, Tilg H. Schwärzler J, et al. Expert Rev Clin Immunol. 2024 Apr;20(4):375-386. doi: 10.1080/1744666X.2023.2294046. Epub 2023 Dec 27. Expert Rev Clin Immunol. 2024. PMID: 38149354 Review.
INTRODUCTION: Metabolic-associated liver diseases have emerged pandemically across the globe and are clinically related to metabolic disorders such as obesity and type 2 diabetes. The new nomenclature and definition (i.e. metabolic dysfunction-associated steatotic liver di …
INTRODUCTION: Metabolic-associated liver diseases have emerged pandemically across the globe and are clinically related to metabolic disorde …
Metabolic dysfunction-associated steatotic liver disease in adults.
Huang DQ, Wong VWS, Rinella ME, Boursier J, Lazarus JV, Yki-Järvinen H, Loomba R. Huang DQ, et al. Nat Rev Dis Primers. 2025 Mar 6;11(1):14. doi: 10.1038/s41572-025-00599-1. Nat Rev Dis Primers. 2025. PMID: 40050362 Review.
MASLD is estimated to affect more than one-third of adults worldwide. MASLD is closely associated with insulin resistance, obesity, gut microbial dysbiosis and genetic risk factors. The obesity epidemic and the growing prevalence of type 2 diabetes mellitus greatly …
MASLD is estimated to affect more than one-third of adults worldwide. MASLD is closely associated with insulin resistance, obe …
NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review.
Sergi CM. Sergi CM. Int J Mol Sci. 2024 Aug 2;25(15):8462. doi: 10.3390/ijms25158462. Int J Mol Sci. 2024. PMID: 39126031 Free PMC article. Review.
Nonalcoholic fatty liver disease (NAFLD), or metabolic dysfunction-associated steatotic liver disease (MASLD), is a liver condition that is linked to overweight, obesity, diabetes mellitus, and metabolic syndrome. ...Children may have an alternative form of progressive NAF …
Nonalcoholic fatty liver disease (NAFLD), or metabolic dysfunction-associated steatotic liver disease (MASLD), is a liver condition t …
Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020.
Kalligeros M, Vassilopoulos A, Vassilopoulos S, Victor DW, Mylonakis E, Noureddin M. Kalligeros M, et al. Clin Gastroenterol Hepatol. 2024 Jun;22(6):1330-1332.e4. doi: 10.1016/j.cgh.2023.11.003. Epub 2023 Nov 8. Clin Gastroenterol Hepatol. 2024. PMID: 37949334
Following the Delphi consensus process, the term steatotic liver disease (SLD) was introduced to replace fatty liver disease, while the term metabolic dysfunction-associated steatotic liver disease (MASLD) emerged as the successor to the term nonalcoholic fatty liver disea …
Following the Delphi consensus process, the term steatotic liver disease (SLD) was introduced to replace fatty liver disease, while the term …
Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.
Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME. Kanwal F, et al. Hepatology. 2024 May 1;79(5):1212-1219. doi: 10.1097/HEP.0000000000000670. Epub 2023 Nov 9. Hepatology. 2024. PMID: 38445559
This commentary discusses how clinicians and various stakeholders can utilize the recently published American Association for the Study of Liver Diseases nonalcoholic fatty liver disease (AASLD NAFLD) Practice Guidance in light of the change in the nomenclature to steatoti …
This commentary discusses how clinicians and various stakeholders can utilize the recently published American Association for the Study of L …
Adoption of the New Nomenclature of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) by the Indian National Association for Study of the Liver (INASL): Implications for the INASL Guidance Paper on NAFLD.
Duseja A, De A, Singh SP, Madan K, Rao PN, Shukla A, Choudhuri G, Saigal S, Shalimar, Arora A, Anand AC, Das A, Kumar A, Eapen CE, Devadas K, Shenoy KT, Panigrahi M, Wadhawan M, Rathi M, Choudhary NS, Saraf N, Nath P, Kar S, Alam S, Shah S, Nijhawan S, Acharya SK, Aggarwal V, Saraswat VA, Chawla YK. Duseja A, et al. J Clin Exp Hepatol. 2025 Sep-Oct;15(5):102590. doi: 10.1016/j.jceh.2025.102590. Epub 2025 May 16. J Clin Exp Hepatol. 2025. PMID: 40535844 Review.
The transition from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) reflects a paradigm shift in hepatology, emphasising metabolic dysfunction as the central driver in patients with MASLD. This inclusive t …
The transition from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) refl …
NAFLD No More: A Review of Current Guidelines in the Diagnosis and Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Kaylan KB, Paul S. Kaylan KB, et al. Curr Diab Rep. 2024 Nov 13;25(1):5. doi: 10.1007/s11892-024-01558-y. Curr Diab Rep. 2024. PMID: 39535566 Review.
RECENT FINDINGS: Nomenclature changes have placed a greater focus on cardiometabolic risk factors in the definition of MASLD. ...MASLD has been increasing in prevalence and disease burden but is underrecognized in primary care and endocrinology clinics. ...
RECENT FINDINGS: Nomenclature changes have placed a greater focus on cardiometabolic risk factors in the definition of MASLD. …
180 results